Related Experiment Video
Updated: Jun 17, 2026
08:48
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Emerging peptide therapeutics for inflammatory autoimmune diseases
Jean-Paul Briand1, Sylviane Muller
1CNRS, Institut de Biologie Moléculaire et Cellulaire, UPR9021 Immunologie et Chimie Thérapeutiques, Strasbourg, France.
Current Pharmaceutical Design
|December 25, 2009
Summary
Peptide therapeutics offer a promising, targeted approach to treating inflammatory diseases, moving beyond palliative care. These agents modulate the immune system more precisely, aiming for curative outcomes with fewer adverse effects.
Area of Science:
- Immunology
- Pharmacology
- Biotechnology
Background:
- Current treatments for inflammatory diseases are palliative and cause nonspecific immunosuppression with adverse effects.
- Novel strategies focus on targeted molecular pathways and cells to restore immune tolerance.
- Peptide therapeutics are emerging as a valuable class of agents for chronic inflammatory conditions.
Purpose of the Study:
- To review emerging peptide therapeutics for inflammatory diseases.
- To discuss the advantages of peptide agents in immunotherapy.
- To explore future challenges in peptide drug development and administration.
Main Methods:
- Review of current literature on peptide therapeutics in preclinical and clinical studies.
- Analysis of the properties and potential modifications of peptide agents.
- Discussion of challenges in optimizing peptide dosage, administration, stability, and targeting.
Main Results:
- Peptide therapeutics demonstrate favorable properties for long-term treatment and immune modulation.
- Several peptide candidates are under investigation in animal models and human clinical trials.
- Peptide-mediated immunotherapy shows potential for restoring immune tolerance.
Conclusions:
- Peptide therapeutics represent a significant advancement over current palliative treatments for inflammatory diseases.
- Further research is needed to optimize peptide drug selection, dosage, administration, and bioavailability.
- Targeted peptide-based immunotherapies hold promise for treating chronic inflammatory diseases effectively.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...